Latest Manufacturing Processes News

ClearVue Technologies has appointed Douglas Hunt as its permanent Global CEO, unveiling a refreshed leadership team focused on scaling sales, manufacturing, and product innovation. The new executives have agreed to sub-market pay until the share price hits 35 cents, signaling strong alignment with shareholder interests.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Wide Open Agriculture has achieved a breakthrough in lupin protein production, slashing energy consumption by up to 80% and halving processing time in a recent commercial-scale trial. These efficiency gains pave the way for more cost-effective, scalable manufacturing.

INOVIQ Limited has announced a breakthrough in its cancer treatment program, with its CAR-exosome therapy killing 88% of triple negative breast and lung cancer cells in laboratory studies. This innovation could pave the way for faster, safer, and more accessible cancer therapies.

BluGlass Limited has extended its Share Purchase Plan closing date to June 18, 2025, securing an extra $1.5 million in institutional commitments to accelerate production of its gallium nitride lasers.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Aurora Labs has been awarded a $544,333 Defence Industry Development Grant to expand its production capabilities for gas turbine propulsion systems, reinforcing Australia’s sovereign defence manufacturing.

SPC Global Holdings confirms FY2025 pro forma EBITDA guidance of A$29 million, driven by strong early post-merger performance and strategic initiatives including site consolidation and leadership renewal.

Foresta Group Holdings’ subsidiary partners with New Zealand’s EECA to explore geothermal steam for its flagship biomass facility, aiming to boost sustainability and efficiency.

Strategic Elements Ltd (ASX: SOR) reported meaningful progress in its Energy Ink™ technology and underground mining platform during Q1 2025, while maintaining a robust cash balance and preparing for international collaborations.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Titomic Limited advances its strategic U.S. footprint with a new Huntsville facility set to open in June 2025, securing major defense collaborations and expanding commercial momentum in additive manufacturing.